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Novelty and impact of the work: This cohort study covering an entire population presents the risk of 
malignancies diagnosed under age 20 in patients with neurofibromatosis type 1. The results establish that 
malignancies do cause increased mortality in this age group. Tumors were most prevalent in the central 
nervous system. Even after exclusion of optic pathway gliomas, the standardized incidence ratio for central 
nervous system tumors was 59.1. Malignant peripheral nerve sheath tumors occurred already in 
adolescence. There was not a single case of leukemia. 
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Abstract 
Neurofibromatosis type 1 (NF1) is a cancer predisposition syndrome with an incidence of 1:2000. Patients 
with NF1 have an increased cancer risk and mortality, but there are no population-based cohort studies 
specifically investigating the risk of childhood malignancies.  
We used the Finnish NF1 cohort to analyze the incidence, risk and prognosis of malignancies in NF1 
patients <20 years of age. Persons born in 1987–2011 were included, and 524 persons were followed 
through the files of the Finnish Cancer Registry from birth up to age 20 years. This amounted to 8,376 
person years.  
Fifty-three patients had cancer <20 years of age, yielding a standardized incidence ratio (SIR) of 35.6. 
The most frequent location of pediatric cancers was the central nervous system (CNS); there were 45 cases 
and the SIR was 115.7. Exclusion of 22 optic pathway gliomas (OPGs) gave an SIR of 59.1 for the CNS and 
21.6 for all cancers. There were nine malignant peripheral nerve sheath tumors (MPNSTs); their cumulative 
risk was 2.7% by age 20. No cases of leukemia were observed. NF1 patients showed considerable excess 
mortality with a standardized mortality ratio (SMR) of 73.1. The survival of NF1 patients with CNS tumors 
other than OPGs did not differ from that of non-NF1 controls (HR 0.64, 95% CI 0.23 to 1.76). 
In conclusion, brain tumors in childhood and MPNSTs in adolescence are malignancies of major concern 
in patients with NF1. The risk for myeloid malignancies may not be as high as suggested in the literature.  
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Introduction 
Neurofibromatosis type 1 (NF1; Mendelian Inheritance in Man, 162200) is a cancer predisposition 
syndrome with an incidence of 1:2000 as reported in Finland,1 and a prevalence of 1:2000–4000.2,3 The 
inheritance of NF1 follows an autosomal dominant trait, but in ~50 % of the patients the syndrome is 
caused by a de novo mutation which may delay the diagnosis especially in children. The NF1 gene 
underlying the syndrome is located on chromosome 17 and encodes neurofibromin tumor suppressor 
protein. Neurofibromin functions as a Ras-GTPase activating protein (RasGAP), and NF1 mutations lead to 
over-activation of the Ras signaling pathway.4,5 
Patients with NF1 have a high risk for nervous system malignancies which are uncommon in the general 
population, such as malignant peripheral nerve sheath tumors (MPNSTs) and astrocytomas.6,7 Brain  and 
CNS tumors have been reported in approximately 20% of patients with NF1 and are usually detected in 
early childhood.8–10 Optic pathway gliomas (OPGs) account for about 70% of all CNS tumors in children with 
NF1 while the second most common brain tumor is brainstem glioma, representing about 17% of all CNS 
tumors.10,11 OPG of NF1 patients is morphologically nearly always grade 1 pilocytic astrocytoma. The 
incidence of OPG in NF1 may be as high as 15–20%, and it frequently develops before the age of 7 years, 
but can present at any age.9 The course of NF1-associated OPGs is more favorable than that of sporadic 
ones: in NF1 patients, OPG is most often asymptomatic and less than half require treatment.8,12,13 Similarly, 
the brain stem glioma has a more benign course in NF1 patients compared to the children without NF1.10 In 
addition to optic nerve and brain stem tumors, low-grade pilocytic astrocytomas and high-grade gliomas 
occur also in other locations of the CNS in NF1.11 However, the survival of the NF1 patients with non-OPG 
brain tumors is poorly understood13 (for review see 14). The incidence and survival related to childhood 
brain tumors among patients with NF1 have not been previously studied in population-based cohorts.  
Most OPGs are recorded as benign tumors, D33 in the International classification of diseases (ICD-10), 
and thus are not registered as cancers in all countries. Despite a possibly benign morphology, intracranial 
tumors can be coded as cancers with the topographic codes C70-C72 in ICD-10; this is the case, for 
example, in Finland and the USA. All indolent OPGs are not registered, but tumors which have been treated 
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or biopsied are more likely to be covered by the Finnish Cancer Registry15. Thus, the present study does not 
attempt to report incidence, survival or mortality associated with OPGs in the study population.  
MPNST is an aggressive tumor which accounts for 38–45% of the cancer deaths of all NF1 patients.6,16 
MPNST in the general population is a rare tumor of the elderly, while the highest risk of MPNST in NF1 
coincides with young adulthood.6,17 MPNST is one of the hallmark complications of NF1 and arises often 
from a congenital plexiform neurofibroma. Patients with NF1 microdeletion, i.e., a large deletion of the NF1 
gene and its flanking regions, are especially susceptible to MPNSTs.18 Treatment of MPNST in children with 
NF1 has not been systematically studied, but the mainstay of treatment is radical operation while the role 
of adjuvant therapy is still unclear. NF1 is an unfavorable prognostic factor of MPNST.19 Our knowledge on 
MPNST in children with NF1 comes mainly from case series studies, 20–23  but an MPNST risk of 0.5% for NF1 
patients under 20 years of age has been estimated in one population-based cohort.24 
Children with NF1 are frequently mentioned in the literature as having an increased risk of malignant 
myeloid disorders, particularly juvenile myelomonocytic leukemia.25 The NF1 gene functions as a tumor 
suppressor in early myelopoiesis and this provides the basis for this connection.26 However, good quality 
population-based epidemiologic data on the incidence of myeloid disorders associated with NF1 are sparse. 
Also, pheochromocytoma is one of the tumors typically associated with NF16 and it has been described in a 
16-year-old teenager with NF127 but there are no reports on its incidence in adolescence. 
The current knowledge of the epidemiology of NF1-related malignancies in children relies mainly on 
hospital register studies, while population-based studies on the incidence, survival and mortality are 
lacking. Our recent population-based study on NF1 and cancer6 described the cancer risk in NF1 in various 
age groups and showed a highly increased cancer incidence and mortality in childhood. The purpose of the 
present study is to analyze the risks of various malignancies in childhood in more detail.  
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Data and statistical methods 
The study adhered to the Declaration of Helsinki principles and was approved by the Ethics Committee of 
the Hospital District of Southwest Finland, the Ministry of Social Affairs and Health and the National 
Institute for Health and Welfare. 
The Finnish NF1 Registry is population-based and encompasses all NF1 patients who have visited the 5 
university and 15 central hospitals in Finland during the ascertainment period of 1987–2011.1 Currently, the 
cohort includes a total of 1,476 patients (770 females, 706 males) whose NF1 diagnosis has been verified 
from patient records according to the diagnostic criteria of the NIH. The NF1 registry was cross-linked with 
national registries using the personal identity code as a key. Dates of death and emigration were obtained 
from the Population Register Center of Finland (https://vrk.fi/en). The Finnish Cancer Registry 
(https://cancerregistry.fi) was searched for cancer diagnoses of the NF1 patients. Population reference 
rates of cancer incidence and mortality were generated by the Cancer Registry. 
All intracranial tumors can be registered as cancers with ICD-10 topographic codes C70-C72, regardless 
of morphology. However, underreporting of tumors which are not histologically verified, e.g., non-
malignant tumors of the central nervous system has been noted in the Finnish Cancer Registry. Specifically, 
78.9 % of all benign brain tumors were registered in the Finnish Cancer Registry15. OPGs are thus not 
comprehensively covered, but tumors that have been biopsied or treated are more likely to be included. 
Especially in the older cases, biopsy does not necessarily imply that the tumor has been symptomatic. 
Because the coding of intracranial tumors is not always fully accurate due to a lack of biopsy or surgery, the 
medical records of the NF1 patients with tumors of the brain and CNS were manually reviewed in order to 
identify OPGs. All analyses were carried out with and without OPGs. 
Cancer incidence and risk 
For the calculation of the standardized incidence ratio (SIR) and cumulative risk, the NF1 patients born 
during the ascertainment period 1987–2011 were followed up from birth to death, emigration, 20th 
birthday or the end of follow-up on December 31st, 2014, whichever occurred first. The follow-up was 
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started at birth in order to cover the entire spectrum of childhood cancer in NF1. Because the diagnoses of 
the NF1 children born during the ascertainment period have been comprehensively established,1,3 
restricting the analysis to only those born 1987-2011 should reduce the risk of missing patients. However, it 
is possible that we have missed some patients whose NF1 has not been diagnosed by the end of the 
ascertainment period because of mild symptoms. Since children with cancer or other life-threatening 
condition are thoroughly examined in hospitals, we believe that undiagnosed NF1 is highly unlikely even 
among those who die of cancer during their first years of life.  
The SIR was calculated as the ratio of observed to expected cases, where the expected cases were 
obtained by multiplying the person-years observed in the NF1 cohort with the corresponding population 
rate of cancer incidence, stratified by age, calendar-period and gender. The 95% confidence intervals (CI) 
were computed by assuming that the number of observed cases followed the Poisson distribution. The 
homogeneity of the SIRs between the genders was tested using the standard likelihood ratio test of the 
Poisson regression model. The cumulative risk of cancer by age 20 years was calculated with death as a 
competing risk. 
Mortality and survival 
In order to avoid immortality bias when assessing the standardized mortality ratio (SMR), the follow-up of 
the NF1 patients started at the first NF1-related hospital visit 1987–2011, i.e., the hospital visit that led to 
the inclusion of the patient into the cohort. All NF1 patients below the age of 20 years at cohort entry were 
included in the analysis, irrespective of their year of birth. The follow-up ended at death, emigration, 20th 
birthday or the end of follow-up on December 31st, 2014, whichever occurred first. Only deaths due to 
cancer were considered as events for the SMR analysis. The SMR for cancer was calculated as the ratio of 
observed to expected number of deaths using the general population rates matched for age, calendar-
period and gender as a reference. In the SMR analysis related to tumors of the brain and CNS, an event was 
defined as a cancer-related death of a patient with a tumor of the brain and CNS. The 95% CI of SMR was 
obtained using the Poisson distribution, as for SIR. 
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The survival of patients with NF1 and tumors of the brain and CNS was compared with the survival of 
matched controls. The controls were patients with tumors of the brain and CNS from the Finnish Cancer 
Registry matched for gender, age at diagnosis (within 5 years) and diagnosis year (within 5 years). All 
available controls without NF1 were included. The follow-up started at the time of tumor diagnosis, when 
the patient was <20 years of age and ended at death or censoring due to emigration or the end of follow-up 
on December 31st, 2014. Cumulative, cancer-specific survival proportions with 95% CI were calculated using 
the weighted Kaplan-Meier method in which matched controls of each NF1 patient were weighted using 
the inverse of the size of the NF1 patient’s control group. The matched Cox regression model28 was used to 
compare the groups. Statistical analyses were conducted with the statistical software R, version 3.4.2 
(https://www.r-project.org/) and the popEpi package, version 0.4.4.  
Results  
Childhood cancer incidence and risk 
A total of 524 NF1 patients (238 females, 286 males) were born during the ascertainment period (1987–
2011), yielding 8,376 person-years of follow-up. The cancer registry linkage revealed 56 tumors diagnosed 
in 53 patients (31 females, 22 males) aged less than 20 years (Figure 1). The median age at cancer diagnosis 
of females was 5.8 years (range 0.67 to 18) and of males 9.3 years (range 2.5 to 19) (P=0.23). The childhood 
cancer incidence among NF1 patients was significantly higher than in the general population of similar age 
and calendar-period with an SIR of 35.6 (95% CI 27.1 to 45.8) (Table 1). The cancer SIR of females was 
significantly higher than of males (P=0.012). The cumulative risk of a patient with NF1 being diagnosed with 
cancer or an intracranial tumor was 12.1% (95% CI 8.9% to 15.2%) by age 20 years – 9.4% (95% CI 5.4% to 
13.1%) among males and 15.3% (95% CI 10.0% to 20.3%) among females. The SIRs stratified by tumor 
location are shown in Table 2. 
Out of the 56 tumors, 22 were OPGs. After exclusion of OPGs, the remaining 34 tumors (non-OPG 
tumors) yielded an SIR of 21.6 (95% CI 15.1 to 29.7) (Table 1), and the gender difference was no longer 
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significant (P=0.11). The risk of a patient with NF1 being diagnosed with a non-OPG tumor was 8.1% (95% CI 
5.3% to 10.8%) by age 20 years. 
Cancer mortality 
Among the 741 NF1 patients (351 females, 390 males) who entered the cohort before age 20 years, 21 
deaths occurred under 20 years of age. There were 7,742 person-years of follow-up (3,444 among females 
and 4,298 among males). Seventeen of the 21 deaths were due to cancer, highlighting the significantly 
higher cancer mortality compared to the general population: the SMR for cancer death was 73.1 (95% CI 
42.6 to 117.1). There was no statistically significant difference between the genders (females: 9 deaths, 
SMR 94.0, 95% CI 45.2 to 169.4; males: 8 deaths, SMR 58.5, 95% CI 26.7 to 108.9; P=0.33). The risk of death 
from tumor by age 20 was 4.0% (95% CI 2.5% to 6.6%).  
CNS tumors  
The most common location of NF1-associated malignant tumors, according to the Finnish Cancer Registry, 
was the CNS (ICD-10 C70-C72) with 45 tumors out of a total of 56 tumors. The median age of the patients at 
the time of diagnosis of OPGs was 4.5 years (range 1.3 to 15), and of the 22 patients with OPG, 14 were 
females and 8 were males. The median age at the time of diagnosis of other tumors of the brain and CNS 
was 9.3 years (range 2.5 to 18) in 12 females and 11 males. While the overall SIR of tumors of the brain and 
CNS was 115.7 (95% CI 86.4 to 155.0), the SIR value sank after exclusion of the OPGs to 59.1 (95% CI 39.3 to 
89.0) (Table 2).  
The detailed locations and grades of the CNS tumors are presented in Table 3. Most of the tumors (11) 
were pilocytic astrocytomas. One high-grade (WHO grade III-IV) glioma was observed during follow-up. In 
addition, three high-grade gliomas in patients aged <20 years were known to have occurred outside the 
follow-up time. The locations of the CNS tumors are shown in Figure 2. In addition to gliomas, five 
neurofibromas, plexiform neurofibromas or neurilemomas, and one MPNST presenting in the spinal cord 
were located in the CNS. When also the tumors located in the spinal cord were excluded and the analysis 
was limited to the non-OPG tumors of the brain only, the SIR remained high (SIR 49.9, 95% CI 29.8 to 77.6).  
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Mortality related to non-OPG tumors of the CNS at ages below 20 years was significantly higher than in 
the general population, with 5 deaths and an SMR of 72.1 (95% CI 23.4 to 168.2). Four of those who died 
were male (SMR 102.1, 95% CI 31.7 to 237.0) and one was female (SMR 33.1, 95% CI 1.9 to 145.8) (P=0.27). 
The median age at death was 14 years (range 4.0 to 19). Survival of NF1 patients diagnosed with non-OPG 
tumors of the CNS at age <20 years was compared to the survival of patients with matched tumors in the 
general population. Neither the overall nor the cancer-specific 5-year survival of NF1 patients with CNS 
tumors differed from the general population (hazard ratio 0.64 for overall survival, 95% CI 0.23 to 1.76, 
P=0.39). 
Malignancies of the peripheral nervous system 
MPNSTs (ICD-O-3 codes 9540/3 and 9560/3) were detected in 9 patients: 5 females and 4 males, whose 
median age at diagnosis was 15 years (range 12 to 19). The cases were scattered among the ICD-10 
categories of peripheral nerves and autonomic nervous system (C47), soft tissues (C48-C49) and CNS (C70-
C72) (Table 2). An MPNST-specific SIR could not be computed because MPNST is extremely rare in the 
general population among subjects aged less than 20 years, and thus there was not a sufficient number of 
controls. The cumulative risk of an MPNST by age 20 years was 2.7% (95% CI 1.4% to 5.3%). Out of the 9 
patients who had MPNST, 4 died during the follow-up.  
Other malignancies 
One case of adamantinoma of the tibia, one rhabdomyosarcoma and one neuroblastoma were diagnosed. 
Leukemias, pheochromocytomas and gastrointestinal stromal tumors (GISTs) are often mentioned as being 
associated with NF1, but none of these were seen in the patients of the current study.  
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Discussion  
 
Malignancies in pediatric patients with NF1 have been reported in case series from specialized referral 
centers, but cohort studies with data on population-based incidences of NF1 associated malignancies in 
childhood and adolescence have  been sparse.13,16,29 The present study compared the total, population-
based Finnish NF1 cohort with general population data collected by the nationwide Finnish Cancer Registry. 
We believe that the resulting estimates can be generalized to other populations, since the Finnish 
population is very similar to that of other western countries.  
We have previously shown that the cancer risk of patients with NF1 is elevated (SIR 5.03).6 The present 
study focused on the population aged <20 years and showed that the SIR for tumors registered in the 
Finnish Cancer Registry is 35.6. Together, our previous study6 and the current one show that the relative 
risk of cancer among patients with NF1 is the highest in childhood and adolescence, and that children and 
adolescents with NF1 have a substantial risk of also other tumors than OPG. The present study also 
suggests a higher cancer SIR among females than males, which is partly due to the seemingly higher 
incidence of symptomatic OPGs in females. This is in accordance with a previous study showing that 
females have more symptomatic OPGs, and females with NF1 and OPG are more likely than males to 
experience visual decline requiring treatment.30,31 However, gender differences observed in the current 
study and in previous pediatric cohorts may be compromised by sampling bias. Our recent study suggests 
that girls may be diagnosed with NF1 later than boys.3 Thus, girls with mild NF1 symptoms may be more 
likely than boys to be missing from pediatric cohorts. There were fewer females than males also in the 
current study, suggesting that some females with mild symptoms may be missing from the cohort.  
The results of the current study show that the cancer-related mortality is high (SMR for cancer death 
73.1). Cancers were clearly the most frequent cause of death, since 17 out of the 21 deaths of NF1 patients 
aged <20 years were due to cancer. In comparison, accidents are the leading cause of death among children 
and adolescents in general Finnish population, cancer being only the fourth most common cause 
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(http://www.stat.fi/til/ksyyt/index_en.html). There was no significant gender-related difference in 
mortality in the NF1 cohort <20 years of age.  
The vast majority, 45 of 56 of the registered tumors, were located in the CNS, OPG being the most 
common type. Even without the OPGs, the incidence of CNS tumors was 59.1-fold the incidence in the 
corresponding general population. Because OPGs represent the majority of brain tumors in NF1, it is not 
surprising that the main focus of previous studies on childhood CNS tumors has been OPG. OPGs have also 
been included in most of the case series covering all CNS tumors. In the current study, OPGs were 
diagnosed at younger age than non-OPG tumors of the brain and CNS. The median age at the time of 
diagnosis of OPGs was 4.5 years, and of non-OPG tumors 9.3 years (P=0.001). This agrees with a previous 
study on MRI findings, which reported that the number of NF1 patients diagnosed with extra-optic glioma 
was highest in the age group 10–19 years.32  
The results of the current study show that 49% of CNS tumors were OPGs and the remaining 51% were 
evenly distributed to various locations in the CNS. Only 8.9% were brainstem gliomas; previous studies have 
reported somewhat higher numbers of brainstem gliomas (17–18%)10,11. This may be due to differences in 
the inclusion of patients in the present and previous studies, since patients with non-symptomatic 
brainstem gliomas may not have been ascertained in our study. Grade I pilocytic astrocytomas represented 
the most frequent morphology of the tumors (Table 3), and only two high-grade tumors of the CNS were 
detected in the cohort. However, outside the ascertainment and follow-up years of this study, there were 
three high-grade (WHO grade III–IV) gliomas in patients aged <20 years. High-grade gliomas do occur in 
NF1.22,33 It is possible that high-grade tumors are more frequent in adult than pediatric NF1 patients. 
Glioblastomas are typically associated with constitutional mismatch repair deficiency (CMMRD), which has 
overlapping clinical findings with NF1. Specifically, multiple café au lait macules have been reported in more 
than 60% and skinfold freckling in more than 10% of patients with CMMRD.34 In our cohort, the patients 
with high-grade gliomas were not suspected of CMMRD because, in addition to café au lait macules, they 
had neurofibromas and skinfold freckling. 
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The present study shows that non-OPG tumors of the CNS are associated with a high SMR (72.1). 
Previous studies have suggested that gliomas in NF1 patients are associated with better patient survival 
than gliomas diagnosed in patients without NF1. In these studies, however, patients with OPGs have been 
included.13,35,36 In our study, the survival of patients with non-OPG tumors of the brain and CNS does not 
significantly differ from the survival of matched non-NF1 controls. Inclusion of OPGs, which are associated 
with a better prognosis of NF1 patients than non-NF1 patients,13,37 may have led to an apparently more 
favorable outcome reported in previous studies.  
Our cohort included three patients with OPG and another CNS malignancy: one meningioma, one 
MPNST eight years after radiation treatment of a symptomatic OPG (outside the follow-up of the current 
study), and one grade II astrocytoma of the corpus callosum. Unlike OPG patients without NF1, patients 
with NF1 are also at risk of developing a second CNS tumor in addition to OPG.13  
MPNST is an aggressive malignancy specifically associated with NF1. The mortality caused by MPNST in 
the NF1 population is over 2,000-fold compared to the general population.6 Case reports and patient series 
show that MPNSTs may develop already during adolescence, but the risk of MPNST in childhood has not 
been established.16,17,22,38 The present study identified nine MPNSTs in patients aged less than 20 years. The 
median age at diagnosis of these patients was 15 years (range 12 to 19). The cumulative risk of having an 
MPNST by age 20 years was 2.7%, and four MPNSTs were fatal during the follow-up. Thus, MPNST is not a 
rarity in young patients with NF1 – it constitutes a marked threat to NF1 patients already during their 
teenage years. Pheochromocytomas and GISTs are associated with NF1, but based on the current study, 
they are not common in children or teenagers with NF1. However, pheochromocytomas and GISTs may not 
be comprehensively covered by the Finnish Cancer Registry which hampers our ability to draw conclusions 
on incidences. 
NF1 is claimed to predispose to leukemias.25,39 Juvenile myelomonocytic leukemia (JMML) is often 
included in the list of frequent malignancies associated with NF1. Bader and Miller reported originally in 
197839 that the ratio of acute lymphocytic leukemia to nonlymphocytic leukemia was 9:20 in children with 
neurofibromatosis, which is markedly different from the 4:1 ratio in children without neurofibromatosis. 
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This was before the present classification of leukemias in ICD-O-2 and ICD-O-3. JMML (9946/3 in ICD-O-3) is 
a rare myelodysplastic syndrome of childhood, and 14% of patients with JMML have NF1.40 Furthermore, 
9% of all patients with chronic myelomonocytic leukemia (CMML), collected from the network of registers 
in Great Britain, had NF1.41 Based on these numbers, NF1 patients have been estimated to have a 200-fold 
increase in the incidence of CMML compared to the general population.41  
Inactivation of both NF1 alleles has been demonstrated in the bone marrow cells of NF1 patients with 
hematologic malignancies, suggesting a pathogenic role of NF1 in these malignancies.25 However, JMML is a 
rare leukemia in the general population as well as in NF1. Assuming an overall annual incidence of JMML of 
1.2 per million children aged 0–11 years and a 200-fold increase in the incidence among patients with NF1, 
1.4 cases would have been expected to surface in the current study, but no leukemias were observed. Thus, 
we cannot confirm the increased risk for leukemia nor JMML in NF1. There was not a single case of CMML 
neither in the entire Finnish NF1 cohort6 nor in the large population-based study from Great Britain7while 
two fatal cases of JMML were reported in a UK population of 1186 NF1 patients.16 Thus, although NF1 
patients represent an unusually large percentage of patients with JMML, leukemia is not a frequent 
complication of NF1. 
To conclude, brain tumors are the frontline cancers to develop in children with NF1, and MPNSTs are a 
major concern in adolescence. The risk for myeloid malignancies may not be as marked as previously 
suggested in the literature. 
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Figure Legends 
Figure 1. Incidence of tumors registered in the Finnish Cancer Registry by age at diagnosis among patients 
with neurofibromatosis type 1 (NF1). Total tumor incidence and the proportion of tumors other than optic 
pathway gliomas (OPGs) are shown. Whiskers show 95% confidence intervals of the overall incidence, 
computed with the statistical software R package epiR, version 0.9-96. The numbers of tumors diagnosed 
by patient age are shown under the corresponding bar. 
Figure 2. Localization of brain tumors in the study. Numbers of cases in each location are shown in Table 3. 
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Table 1. Observed and expected number of cancers and standardized incidence ratios (SIR) among NF1 
patients aged <20 years by gender and tumor type. (P-value for comparison between genders for all tumors 
P = 0.012). OPG: optic pathway glioma; CI: confidence interval 
 
 
 
  All tumors Non-OPG tumors 
Population Expected Person-years Observed SIR 95% CI Observed SIR 95% CI 
Total 1.57 8,376 56 35.6 27.1 to 45.8 34 21.6 15.1 to 29.7 
Males 0.91 4,610 23 25.3 16.3 to 37.1 15 16.5 9.5 to 26.3 
Females 0.66 3,766 33 49.7 34.6 to 68.6 19 28.6 17.6 to 43.5 
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Table 2. Observed and expected numbers of cancer cases and standardized incidence ratios (SIR) with 95% 
confidence intervals (CI) among Finnish NF1 patients aged <20 years by cancer location. CNS: central 
nervous system; ICD-10: International classification of diseases, 10th edition; OPG: optic pathway glioma 
  
Location ICD-10 codes Expected Observed SIR 95% CI 
Brain, CNS C70-C72 0.39 45 115.7 86.4 to 155.0 
non-OPG tumors in brain, CNS C70-C72 0.39 23 59.1 39.3 to 89.0 
Peripheral nerves and autonomic nervous 
system  
C47 0.03 8 271.7 135.9 to 543.2 
Soft tissues C48-C49 0.06 2 33.8 8.5 to 135.3 
Bone C40-C41 0.04 1 24.7 3.5 to 175.6 
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Table 3. Localization of central nervous system tumors in patients with NF1 aged <20 years by ICD-10 codes 
and tumor grade. 
 
aMPNST in the spinal cord. 
 
 
Localization n (total 
45) 
% Benign Grade I Grade II High-
grade 
Grade not 
known 
Optic pathway 22 48.9  13 3  6 
Brainstem 4 8.9  4    
Cerebral lobes 6 13.3  5  1  
Cerebellum  2 4.4  2    
Midbrain  6 13.3  3 3   
Spinal cord 5 11.1 4   1a  
This article is protected by copyright. All rights reserved
A
cc
ep
te
d 
A
rti
cl
e
I of registered tumors in NF1ncidence by age group
Non-OPG tumors
OPGs
In
c
id
e
n
c
e
 (
c
a
s
e
s
 /
 1
0
0
0
 p
y
rs
)
e
rs
o
n
-
e
a
0
5
30
25
20
15
10
Age (years)
14987654321 131210 11 19181716150
0 2 3 5 4 2 1 1 2 0 0 1 0 0 0 1 0 0 0 0n, OPGs
35
1 0 2 1 2 2 2 2 1 3 2 0 2 1 6 3 1 1 1 1n, non-OPG tumors This article is protected by copyright. All rights reservedA
cc
ep
te
d 
A
rti
cl
e
This article is protected by copyright. All rights reservedA
cc
ep
te
d 
A
rti
cl
e
